

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/676,436 09/29/2000		Donna T. Ward	RTS-0169 5700	
7	7590 07/07/2003			
Jane Massey			EXAMINER	
66 East Main Street Marlton, NJ 08053			LACOURCIERE,	E, KAREN A
			ART UNIT	PAPER NUMBER
			1635	15
			DATE MAILED: 07/07/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

-1							
Office Action Summary		Application	n No.	Applicant(s)			
		09/676,436	3	WARD ET AL.			
		Examiner		Art Unit			
		Karen A. La		1635			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
	Status 1)⊠ Responsive to communication(s) filed on <u>21 April 2003</u> .						
•	This action is FINAL . 2b) \boxtimes This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1,2,4-10 and 12-15</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
	Claim(s) <u>1,2,12 and 14</u> is/are rejected.						
-	Claim(s) <u>4-10,13 and 15</u> is/are objected to.						
8) (Application	Claim(s) are subject to restriction and/or	r election re	quirement.				
		ır					
9) The specification is objected to by the Examiner.10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
10)1	Applicant may not request that any objection to the						
11)□ TI	ne proposed drawing correction filed on		•				
If approved, corrected drawings are required in reply to this Office action.							
12)☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1	1. Certified copies of the priority documents have been received.						
2	2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) D Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s) _	·		y (PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/676,436

Art Unit: 1635

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 20, 2003 has been entered.

Claim Rejections - 35 USC § 102 or 35 USC § 103

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 09/676,436

Art Unit: 1635

Claims 1, 2, 12 and 14 are rejected under 35 U.S.C. 102(b) or 35 USC 103(a) as being anticipated by or obvious over Kucherlapati et al. (6,114,598).

Kucherlapati et al. (6,114,598) disclose a 16-mer oligonucleotide that comprises 12 residues fully complementary to nucleotides within residues 3314 to 3333 of SEQ ID NO:3 (see SEQ ID NO:12 for Kucherlapati et al.). The oligonucleotide disclosed by Kucherlapati et al. meets all of the structural requirements of the instant claims, the oligonucleotides would also be expected to specifically hybridize to nucleic acid encoding MEKK4, as per applicant's definition set forth in the specification as filed. Kucherlapati et al. disclose their oligonucleotide in a composition comprising a pharmaceutically acceptable carrier (e.g. water).

Furthermore, since the prior art oligonucleotides meet all the structural limitations of the claims, the prior art oligonucleotides would then be considered to "inhibit expression" of the gene as claimed, absent evidence to the contrary. See, for example, MPEP § 2112, which states "[w]here applicant claims a composition in terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103, expressed as a 102/103 rejection. 'There is nothing inconsistent in concurrent rejections for obviousness under 35 U.S.C. 103 and for anticipation under 35 U.S.C. 102.' In re Best, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977). This same rationale should also apply to product, apparatus, and process claims claimed in terms of function, property or characteristic. Therefore, a 35 U.S.C. 102/103 rejection is

erlapati et al.

rejected base of the

signed are (703)

plication or , ber is (703) 308-

ière